Acinetobacter baumannii Vaccine: LPS Removal for Native OMP Presentation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current vaccines against Gram-negative bacteria like Acinetobacter baumannii, Klebsiella pneumoniae, and Pseudomonas aeruginosa are limited in their ability to provide universal immunity due to the variability of LPS and capsular polysaccharide antigens, and existing treatments for carbapenem-resistant infections lack effective alternatives to antibiotics.

Innovation Solution

Development of inactivated LPS-deficient Acinetobacter baumannii cells expressing heterologous outer-membrane proteins (OMPs) from other bacteria, which induce a broad immune response against multiple conserved OMPs, presented in their native conformation, offering protection against diverse bacterial strains.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Adaptability or versatility

If vaccines use LPS or capsular polysaccharide antigens from Gram-negative bacteria, then they can induce immune response against specific bacterial variants, but they fail to provide universal immunity due to high variability between clones and variants

Engineering Contradiction:

Improveuniversal immunity coverageVSAvoidimmune response consistency

Core Design Contradiction:

Adaptability or versatilityVSReliability

Solution Approach 1:

The invention extracts and removes the variable LPS and capsular polysaccharide components from the vaccine composition, focusing instead on the conserved outer membrane proteins (OMPs) that remain after LPS removal. This extraction of the problematic variable components allows the vaccine to target only the conserved, universal antigens across different bacterial strains.

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The vaccine uses a single platform (LPS-deficient A. baumannii cells) that can express multiple heterologous OMPs from different Gram-negative bacteria, creating a multivalent vaccine that provides universal protection against multiple pathogens and strains through conserved antigenic targets.

Inventive Principle:

Principle #6Universality (Multi-functionality)

2Reliability

If vaccines use recombinant OMP proteins, then they can provide targeted immunity against specific antigens, but they fail to present antigens in their native conformation and show reduced immunogenicity

Engineering Contradiction:

Improveantigen presentation accuracyVSAvoidvaccine production complexity

Core Design Contradiction:

ReliabilityVSEase of manufacture

Solution Approach 1:

The invention uses LPS-deficient A. baumannii cells as an intermediary host system that expresses heterologous OMPs natively in their correct three-dimensional conformation. This living cell platform serves as a mediator that automatically folds and presents the antigens in their native state, eliminating the need for complex purification and reconstitution processes required for recombinant proteins.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The bacterial host system automatically performs the complex tasks of protein folding, post-translational modification, and antigen presentation in its native environment, eliminating the need for external intervention to achieve proper antigen conformation. The system self-organizes to present antigens in their immunologically active form.

Inventive Principle:

Principle #25Self-service

3Adaptability or versatility

If vaccines use inactivated whole cells of Lipid-A null mutants, then they can induce broad immunity against multiple OMPs, but the production process becomes more complex due to genetic modification requirements

Engineering Contradiction:

Improvebreadth of immune responseVSAvoidproduction process complexity

Core Design Contradiction:

Adaptability or versatilityVSDevice complexity

Solution Approach 1:

The vaccine platform is pre-modified by removing the LPS synthesis capability (Lipid-A null mutation) before use. This preliminary genetic modification creates a standardized, safe backbone that cannot produce endotoxin, allowing subsequent expression of various heterologous OMPs without additional safety concerns or process changes.

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The invention fundamentally changes the chemical composition parameter of the bacterial cell by eliminating LPS (a major cell wall component), which simultaneously improves safety (no endotoxin) and functionality (enhanced OMP visibility to immune system) while enabling broad antigen presentation.

Inventive Principle:

Principle #35Parameter changes

4Reliability

If antibiotics are used to treat carbapenem-resistant infections, then they can provide immediate therapeutic effect, but the increasing co-resistance to multiple antibiotic classes limits treatment options

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidtreatment option availability

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The invention converts the harmful effect of bacterial resistance to antibiotics into a beneficial vaccine target. By using the same bacteria that have developed resistance as the vaccine platform, expressing their conserved OMPs, the vaccine provides protection against these resistant strains, turning the resistance problem into a solution opportunity.

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Data Source

PatentUS20250312434A1Lipopolysaccharide (LPS) deficient acinetobacter baumannii multivalent vaccine

Publication Date: 2025.10.09 VAXDYN

AI summary

The invention refers to a composition comprising inactivated cells deficient in LPS from the genus Acinetobacter and/or outer membrane vesicles form the same and their use for the manufacture of a medicament, preferably a vaccine, for the prevention of diseases caused by K. pneumoniae, P. aeruginosa, E. coli, and/or A. pleuropneumoniae, and optionally A. baumannii.